亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

滄州那瑞化學科技有限公司  

原料藥、醫藥中間體(格列美脲中間體、多奈哌齊中間體、卡巴拉汀中間體、左乙拉西坦中間體、托拉塞米中間體、維達列汀中間體、沙格列汀中間體、頭孢替坦中間體、西他列汀中間體、格列吡嗪中間體、依帕司他中間體、羅格列酮中間體、吡格列酮中間體、阿格列汀中間體、利拉利汀中間體、瑞格列奈中間體、鹽酸美金中間體、孟魯司特中間體、雷沙吉蘭中間體等)

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:蘭芳
  • 電話:0317-3563899
  • 郵件:trade@senary.com
  • 傳真:0317-3563199
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 反式-4-甲基環己基異...酸酯
反式-4-甲基環己基異...酸酯
單價 面議對比
詢價 暫無
發貨 河北滄州市付款后3天內
品牌 那瑞化學
過期 長期有效
更新 2014-03-13 10:10
 
詳細信息

   反式-4-甲基環己基異...酸酯  

Trans-4-Methycyclohexyl isocyanate   

Cas No.:32175-00-1     

分子式:C8H13NO

分子量:139.19

外觀:無色透明液體

含量(%):≥99.5%

產品包裝:20kg/襯塑鋼桶

異構體:≤0.2%

用途: 用作藥物格列美脲中間體

格列美脲中間體,全球最大的供應商,產能最大質量最優,已與國內外客戶建立了長期穩定的合作關系。


©2025 滄州那瑞化學科技有限公司 版權所有   技術支持:化工網   訪問量:11926  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |